Skip to content

San Bernardino Sun

55°F
Tuesday, February 10th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

2.308 +0.139 (+6.38%)
Streaming Delayed Price Updated: 11:37 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences in November
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy 
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight ↗
If you believe in chasing the winners higher, here are three hypergrowth stocks that may provide Nvidia-like gains. 
Via InvestorPlace
News headline image
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains ↗
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
Via InvestorPlace
News headline image
CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024 ↗
CNTX stock results show that Context Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces $100 Million Private Placement
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development 
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023 ↗
CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.